| Role for positron emission tomography in skeletal diseases. | |
| | |
MedLine Citation:
|
PMID: 17224294 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Imaging plays a prominent role in the diagnosis and management of rheumatic diseases. Conventional imaging methods provide high-resolution structural information but usually fail to distinguish between active lesions and residual changes. Positron emission tomography (PET) with the tracer 18F-fluorodeoxyglucose (18F-FDG) was recently introduced into clinical practice as a means of obtaining information on both structure and metabolic activity. 18F-FDG-PET is widely used in oncology and may be valuable in patients with infections or inflammatory diseases, most notably vasculitis. Although encouraging results have been published, the number of studies remains small, as 18F-FDG-PET is an expensive investigation that is not available everywhere. Further work is needed to determine the cost-effectiveness ratio of 18F-FDG-PET in patients with infections or inflammatory diseases. Imaging plays a prominent role in the diagnosis and management of many musculoskeletal diseases. Although considerable progress has been made recently, the structural information supplied by conventional imaging methods is inadequate in some patients. Positron emission tomography (PET) after injection of 18fluorodeoxyglucose (18F-FDG) provides information on tissue metabolism. The usefulness of 18F-FDG-PET in oncology is now widely recognized. Other uses are emerging, in part thanks to the development of new cameras that combine dedicated detectors and an X-scanner in order to ensure accurate three-dimensional localization of metabolically active lesions. However, the exact role for 18F-FDG-PET needs to be studied in larger populations of patients. |
| | |
Authors:
|
Michèle Duet; Jacques Pouchot; Frédéric Lioté; Marc Faraggi |
Related Documents
:
|
11893364 - Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, a... 14581764 - Influence of somatostatin receptor scintigraphy and ct/mri on the clinical management o... 18678354 - [(11)c]choline positron emission tomography/computed tomography for staging and restagi... 16762614 - The role of positron emission tomography in the management of pancreatic cancer. 19281464 - Description of magnetic resonance imaging-derived enhancement variables in pathological... 11981274 - The potential of proton magnetic resonance spectroscopy ((1)h-mrs) in the diagnosis and... |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-11-30 |
Journal Detail:
|
Title: Joint, bone, spine : revue du rhumatisme Volume: 74 ISSN: 1778-7254 ISO Abbreviation: Joint Bone Spine Publication Date: 2007 Jan |
Date Detail:
|
Created Date: 2007-02-19 Completed Date: 2007-04-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100938016 Medline TA: Joint Bone Spine Country: France |
Other Details:
|
Languages: eng Pagination: 14-23 Citation Subset: IM |
Affiliation:
|
Nuclear Medicine Unit, European Georges Pompidou Teaching Hospital, Paris, France. michele.duet@lrb.aphp.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Arthritis
/
radionuclide imaging Bone Diseases / radionuclide imaging* Bone Diseases, Infectious / radionuclide imaging Bone Neoplasms / radionuclide imaging Fluorodeoxyglucose F18 / diagnostic use*, metabolism Humans Positron-Emission Tomography / methods* Radiopharmaceuticals / diagnostic use*, metabolism Rheumatic Diseases / radionuclide imaging Sensitivity and Specificity Vasculitis / radionuclide imaging |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Engraftment of cutaneous fibroblasts within synovial membrane in a nonhuman primate: short-term resu...
Next Document: Electrosynthetic reduction of 1-iodoadamantane forming 1,1'-biadamantane and adamantane in aprotic s...